This post was originally published on this site Using chemotherapy in combination with hormone therapy in women with highly recurring forms of breast cancer reduces the likelihood of disease returning elsewhere in the body over nine years compared with hormone therapy alone, a Phase 3 trial shows. The research, “Clinical Outcomes by Chemotherapy Regimen in Patients with RS…
This post was originally published on this site Multiple myeloma patients who failed to respond to treatment with oral Revlimid (lenalidomide) may benefit from by being treated soon afterward with oral Pomalyst (pomalidomide) and low-dose dexamethasone, results of a Phase 2 clinical trial in a first patient group suggest. An overall response “was achieved by 32·1% of…
This post was originally published on this site A $35 million gift from Marc and Lynne Benioff will support a new initiative at the University of California, San Francisco (UCSF) aimed at finding personalized treatments for prostate cancer. “With this gift, we are honoring the memory of Marc’s father and all of those who have…
This post was originally published on this site The small molecule inhibitor Copiktra (duvelisib) has been given orphan status by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma, the therapy’s developer, Verastem Oncology, has announced. This is in addition to a prior fast track designation granted in 2017 for the…
This post was originally published on this site The oral ovarian cancer treatment Zejula (niraparib) has been given Breakthrough Therapy status by the U.S. Food and Drug Administration (FDA) for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who carry BRCA mutations and have been previously treated with certain therapies, namely taxane chemotherapy and androgen-receptor…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted fast track designation to navicixizumab (OMP-305B83) as a potential therapy for heavily pretreated ovarian cancer, Mereo BioPharma, the therapy’s developer, announced. Fast track designation is given to investigational compounds that show considerable potential in treating serious conditions for which available…
This post was originally published on this site IASO Biotherapeutics and Innovent Biologics are preparing the launch of a Phase 1b/2 clinical trial in China to evaluate the companies’ novel CAR T-cell product, CT103A, in people with relapsed or refractory multiple myeloma. The announcement comes after the therapy was granted Investigational New Drug status by…
This post was originally published on this site The Chinese National Medical Products Administration (NMPA) has approved Keytruda (pembrolizumab) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC), Merck (known as MSD outside the U.S. and Canada) announced. The approval covers patients who have tumors with at least 1% of cells producing the PD-L1 protein,…
This post was originally published on this site In observance of National Breast Cancer Awareness Month, the Los Angeles oceanfront resort Terranea will again “turn pink” to benefit breast cancer organizations. Throughout October, Terranea will — for the fourth year — reprise its “Terranea Turns Pink” initiative, which donates a portion of proceeds from golf…
This post was originally published on this site Radiotherapy following chemotherapy reduces the risk of cancer progression in people with early-stage favorable Hodgkin’s lymphoma, regardless of an individual’s response to chemotherapy, results of a Phase 3 study show. These findings support the importance of consolidation radiotherapy — which appears to prevent potential cancer relapse or…
